We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APDNW
126
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$162K 0.02%
648,824
+6,535
+1% +$2.13K
FCEL icon
127
FuelCell Energy
FCEL
$1.57B
$158K 0.02%
+254
New +$161K
SPHS
128
PUT
DELISTED
Sophiris Bio, Inc.
SPHS
$147K 0.02%
729
+454
+165% +$984
SGLBW
129
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$142K 0.02%
375,718
-7,150
-2% -$2.97K
FOCL
130
EDAP TMS S.A.
FOCL
$227M
$141K 0.02%
+60,600
New +$152K
VTGN icon
131
VistaGen Therapeutics
VTGN
$9.55M
$133K 0.02%
4,783
-65,746
-93% -$2.44M
ASXC
132
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$124K 0.01%
56
-179
-76% -$4.1K
GALT icon
133
PUT
Galectin Therapeutics
GALT
$223M
$100K 0.01%
210
-921
-81% -$4.29K
RXIIW
134
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$88K 0.01%
196,522
-1,904,275
-91% -$1.24M
FRTX
135
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$87K 0.01%
190
-683
-78% -$339K
PTCT icon
136
CALL
PTC Therapeutics
PTCT
$6.25B
$84K 0.01%
+1,475
New +$37.4K
PRTA icon
137
CALL
Prothena Corp
PRTA
$448M
$74K 0.01%
240
– –
BCLI
138
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$70K 0.01%
+1,488
New +$74.9K
AMRN
139
Amarin Corp
AMRN
$293M
$61K 0.01%
+1,015
New +$75.3K
SPHS
140
CALL
DELISTED
Sophiris Bio, Inc.
SPHS
$58K 0.01%
+290
New +$628
MBAI
141
Check-Cap
MBAI
$8.12M
$39K ﹤0.01%
314
-3,884
-93% -$710K
PLUR icon
142
Pluri
PLUR
$18.1M
$38K ﹤0.01%
+346
New +$39.8K
VNRX icon
143
VolitionRx Ltd
VNRX
$10.3M
$32K ﹤0.01%
+658
New +$38.5K
XYLO
144
DELISTED
Xylo Technologies
XYLO
$30K ﹤0.01%
148
-83
-36% -$18.9K
NSPRZ
145
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$30K ﹤0.01%
1,998,417
-5,431
-0.3% -$150
BIOC
146
DELISTED
Biocept, Inc.
BIOC
$27K ﹤0.01%
10
-97
-91% -$364K
BNTCW
147
CALL
DELISTED
Benitec Biopharma Limited
BNTCW
$21K ﹤0.01%
+87,693
New +$31.1K
NSPRW
148
DELISTED
InspireMD, Inc. Warrants
NSPRW
$18K ﹤0.01%
911,373
-282,097
-24% -$8.29K
PLUR icon
149
PUT
Pluri
PLUR
$18.1M
$17K ﹤0.01%
+2
New +$230
CYTXW
150
CALL
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$14K ﹤0.01%
+520,858
New +$14.7K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.